Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 8, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
Kineta Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
Themis Bioscience GmbH
Vaccitech Ltd
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) - Overview
Middle East Respiratory Syndrome (MERS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
Autoimmune Technologies LLC
Gilead Sciences Inc
Inovio Pharmaceuticals Inc
Kineta Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
Themis Bioscience GmbH
Vaccitech Ltd
Middle East Respiratory Syndrome (MERS) - Drug Profiles
3B-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNSP-333S1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Middle East Respiratory Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GreMERSfi - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-4301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCA-60 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome coronavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remdesivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAB-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Middle East Respiratory Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East Respiratory Syndrome (MERS) - Dormant Projects
Middle East Respiratory Syndrome (MERS) - Product Development Milestones
Featured News & Press Releases
Jan 10, 2018: First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial
Sep 18, 2017: Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300
Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment
Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
Jun 04, 2015: Kineta’s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Kineta Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Themis Bioscience GmbH, H1 2018
Middle East Respiratory Syndrome (MERS) - Pipeline by Vaccitech Ltd, H1 2018
Middle East Respiratory Syndrome (MERS) - Dormant Projects, H1 2018
List of Figures
Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
